Pfizer hit some unexpected roadblocks with its first U.S. biosimilar launch, but it’s not giving up in the budding field. Now, the drugmaker is launching biosims to three Roche cancer blockbusters at discounts ranging from 22% to 24%. The company has already rolled out Zirabev and Ruxience, its biosimilars to Roche’s Avastin and Rituxan, respectively, at discounts of 23% and 24%. On… Read More »
The risk of middle aged women getting cardiovascular disease such as stroke, heart failure and heart attack could be reduced by the lowering of blood pressure. Researchers determined that high systolic blood pressure in middle-aged and older women is a strong risk factor for cardiovascular issues.[1] The percentage of potentially reversible as well as preventable… Read More »
Health care members make first aid to people as they cover their faces with sanitary masks after the first cases of coronavirus have been confirmed in Hong Kong. Miguel Candela | Getty Images President Xi Jinping on Saturday warned that the spread of the coronavirus presents a “grave situation,” as officials from central China to… Read More »
FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 23, 2020– Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Tazverik (tazemetostat) for the treatment of adults and pediatric… Read More »
The ability to leverage disaster recovery between multiple locations The data center of a highly redundant cloud service provider rarely will experience an outage. However, it is far more likely that the traditional causes of implementing disaster recovery will occur—user error, software errors and even ransomware can happen in a cloud environment. In those cases,… Read More »